COVID-19
Conditions
Interventions
control arm:symptomatic treatment
trial arm:symptomatic treatment + Disease detoxification decoction
Sponsors
Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Hebei
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1 Subjects tested positive for novel coronavirus nucleic acid or antigen ; 2 according to the current version of the ' new coronavirus pneumonia diagnosis and treatment program ', the clinical classification was mild or common type ; 3 Age = 18 years old ; 4 Subjects were able to follow all visiting arrangements, treatment plans, laboratory tests and other research procedures, and voluntarily signed written informed consent.
Exclusion criteria
Exclusion criteria: 1 Aphasia or other patients who could not cooperate to complete the scale evaluation ; 2 Patients who were receiving COVID-19 monoclonal antibody, convalescent plasma, or other prohibited combined drugs within 28 days before screening ; 3 have a history of adverse reactions to known Chinese medicine ingredients ; 4 severe lung disease before onset ; 5 Patients who participated in clinical trials of other drugs within 4 weeks before screening ; 6. Screening patients who had used drugs with pharmacological or clinical effects against the novel coronavirus or traditional Chinese medicine containing components similar to the test drugs within 7 days before the examination, including but not limited to Jinhua Qinggan, Lianhua Qingwen, Banlangen, Azvudine ; 7 patients with immunodeficiency ( such as : malignant tumors, AIDS patients, organ or bone marrow transplants, long-term use of corticosteroids or other immunosuppressive drugs causing immune dysfunction ) ; 8 Suspected or had a history of alcohol, drug abuse or mental illness ; 9 any history of gastrointestinal diseases affecting drug absorption ( including but not limited to reflux esophagitis, chronic diarrhea, inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome, subtotal gastrectomy, etc. ) ; 10 chronic kidney disease ( including chronic kidney disease stage 3-5 ), chronic liver disease ( such as liver fibrosis, cirrhosis, or serum AST and / or ALT = 3 times the upper limit of normal ; pregnant or lactating women ; the researchers believed that other patients were not suitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Median time and 7 d negative conversion rate of novel coronavirus nucleic acid; | — |
Secondary
| Measure | Time frame |
|---|---|
| Main TCM symptom score;Disappearance time of fever symptoms;Incidence of COVID-19 related severe and critical illness; | — |
Countries
China
Contacts
Public Contactwang lixin
Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Hebei
Outcome results
None listed